Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This is a single institution, open-label, single arm, study assessing the safety,
feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with
newly diagnosed, unmethylated glioblastoma.